一虎一席谈

'In-Depth Narcotics Experience': McKinsey Advised US Pharmas on How to Turbo Sell Opioids_我的网站

A |     Global consulting giant McKinsey & Company advised several painkillers producers for 15 years on how to "turbocharge" prescription drug sales largely to blame for starting the opioid epidemic in the US, The New York Times has revealed citing over 100,000 documents.,The docs emerged as a part of a settlement deal that McKinsey signed with several state attorneys that sued the company.,Apart from working with Endo, Purdue, and Mallinckrodt, the company also provided "in-depth experience in narcotics" for Johnson & Johnson subsidiaries producing controlled substances. Meanwhile, hundreds of thousands of US citizens died from overdose, often linked to these very drugs.,How It All Started,According to the disclosed documents, McKinsey helped both Endo and Purdue, the creators of two of the most widespread opioid-based drugs for severe chronic pain, to launch their products Opana and OxyContin in 2006-2008. The firm even advised one of the companies on how to overcome a Food and Drug Administration (FDA) block which it had encountered in 2008.,The FDA blocked Purdue's attempt to release an upgraded version of its OxyContin, which was more difficult to snort or dilute and inject in bloodstream – two methods of the prescription drug's abuse that already had been devised by some of its recipients. In order to help Purdue get the license, McKinsey interviewed an ex-drug dealer on the medication's abuse, prepared docs and even coached the drug firm's officials for meetings with the FDA as the pharmaceutical company knew its drug had been widely abused, the docs suggest.,Crack Pipes: Biden Administration's Handling of US Opioid Crisis Raising Questions, Journo Says15 February, 13:00 GMT,Purdue's main competitor, Endo, also released a new version of its painkiller and tried to get it marked as resistant to crushing (for snorting) and diluting (for injections), but the FDA did not allow the latter citing lack of such properties. Nonetheless, the drug's release was a success and coincided with a drop in abuse-resistant OxyContin's sales.,This came, however, at a cost of local epidemics of previously unseen blood disorders in several US states in 2012 – patients were found to be anemic and suffered from kidney failure. Many of them admitted to abusing updated Opana – the new formulae indeed discouraged from snorting it, but still allowed injection abuse. However, the same component that prevented crushing took a great toll on those who tried to inject the drug to get a better high, leading to red blood cells' destruction and organ damage.,Going on the 'Offensive',The consulting company's involvement in the opioid crisis did not stop at helping the companies to launch their products – it also helped them to boost the sales.,While the pills like the ones produced by Endo, Purdue and Mallinckrodt were originally advertised as not causing additions, US doctors were not always prone to prescribing them, especially when a patient's pain was neither severe nor chronic. According to the revealed documents, McKinsey's consultants helped Purdue, and several other companies, including two J&J subsidiaries, to overcome this "problem".,Starting in 2009, McKinsey developed a "segmentation" strategy for Purdue: its analysts divided the company's customers into groups based on their potential thoughts of the product and then formed distinct messages for each group. The customers in this case were doctors prescribing painkillers and the product was opioid drugs. The strategy targeted even doctors who resorted to opioids only in most extreme cases, ensuring them of OxyContin's safety and trying to convince them that there was no point in making their patients suffer.,The consulting company proposed to achieve this by "[raising] physician comfort levels through appropriate education and support". Purdue tried to convince these doctors that their colleagues had no issues prescribing OxyContin.,By 2014, the US government started to realize a nascent opioid drug problem was underway and introduced new labeling requirements for such drugs as well as instructions to use them only in cases of severe of chronic pain. Around the same time, OxyContin sales started to decline, prompting Purdue to ask for McKinsey's help once again – this time to overcome the government's policy and precautions.,The consultants identified the problem as the company promoting its drug as a less potent opioid amid rampant drug abuse and advised to shift to the "offense" instead, the documents show. They namely advised focusing the salesmen efforts on doctors, who were likely to prescribe OxyContin to a new client not previously taking opioid drugs.,"Physicians with higher OxyContin NBRx to Rx ratio may be more likely to initiate a patient on OxyContin", an extract from a McKinsey presentation for Purdue from January 2014 said.,Around the same time and amid the 2015 HIV concentrated outbreaks in several states linked to the opioid drugs abuse via injections, McKinsey consulted Endo on promoting its Opana. The company was not concerned about what the CDC named "explosive transmission" of HIV and the Opana's role in it, according to the documents. On the contrary, in summer 2015, it helped Endo rededicate most of its salesmen from other products into a "Sales Force Blitz" – the company almost solely dedicated to selling Opana to around 3,000 physicians in the US.,One of McKinsey's consultants was excited over the creation of the "Force", claiming in correspondence with the head of Endo’s painkiller unit that the "fun [begins] on Monday!" with the latter responding "agreed, the fun is just beginning".,Playing Both Sides,One of the strangest revelations in the documents uncovered by the New York Times is that McKinsey managed to play both sides of the opioid crisis tragedy – helping pharmaceutical companies sell more of "not-so-addiction-resistant" drugs, while also assisting the FDA, other government agencies and state governments, in the fight against the epidemic.,In 2017, the FDA finally decided to pull one of the drugs, the more potent Opana, from the market, but not until it made $844 million in revenue with help from McKinsey and played a role in the deaths of thousands of Americans, considered to be the victims of the opioid epidemic. Paradoxically, the same year, McKinsey Senior Partner Tom Latkovic lamented about doctors prescribing opioid painkillers left and right at a health care conference.,"Why do we continue to prescribe, dispense, pay for opioid prescriptions to people that we know, or at least we could know, have an incredibly high propensity to abuse them?" Latkovic wondered.,The bizarre divergence between what McKinsey was advising to the pharmaceutical companies and Latkovic's rhetoric is explained by the fact that he was not a member of the consulting company's pharmaceutical practice, which worked with pharma.,Instead, he and his team worked with state governments and health systems to pin down the ways of tackling the opioid crisis, The New York Times said citing two local officials, who used to work on the issue. Their work, however, was partly complicated by McKinsey's pharmaceutical wing, which wanted to greenlight their draft publications in case they could damage their clients.,North Carolina Rep. Claims Opioid Crisis 'Affects Every Community' in US Amid Drug Trafficking Surge19 December 2021, 01:36 GMT,Eventually in 2019, McKinsey finally stopped advising its top client, Perdue, but not until their ties became public during one of the litigations related to the opioid epidemic and initiated by US authorities. One such litigation eventually had McKinsey pay $600 million in settlement without admitting guilt, as well as release the documents related to its work with the pharmaceutical companies.。    据新西兰警方消息，警方已收到多起涉及华人社区的出租房屋诈骗举报。         这些骗子的目标是那些目前在中国、将要来新西兰的华人，这些华人准备在新西兰(尤其是奥克兰市区)寻找出租屋。

B |          Advertise with us          不幸的是，这不是一个新的骗局。这种骗局通过不同的平台针对受害者。         在这些骗局中，骗子冒充合法的房东或房产中介。         寻找出租房的人通常会被要求通过微信与所谓的房东或中介联系。         骗子会把所谓的身份证明发给租房者，通常是伪造的护照照片或官方文件。

C |          然后，租房者被要求签署一份虚假的租赁协议，并将押金（通常是数千纽币）转到新西兰的银行账户，以确保租房者来到新西兰后的出租屋使用权。         骗子通常会告诉受害者，还有其他新西兰的租客也对该出租屋感兴趣，从而向受害者索要更多的钱来预订房子。         骗子向在中国的租客说，如果他们不付款，房产将被租给新西兰的租客。

D |          通常情况下，受害者会被要求支付第三笔款项，以确保出租房屋配备了家具。

E |          然而，在到达新西兰后，租房者很快就发现他们被骗了，因为他们发现自己预订的出租房已经被他人入住。         警方理解这些骗局可能很容易让人相信。它们可以在世界任何地方进行，并且在许多在线平台上尤其是社交平台上很普遍。         因此，在给别人转钱或达成协议之前，你要注意：          永远不要把钱转到一个你无法核实其合法性的个人或组织。    一个合法的房东或房产中介通常会有一个网站，一个实际地址，你应该能够与来自该组织的多个人交谈。

F |     如果可能的话，找一个在新西兰的朋友或家人去查看所谓的出租房，以证明它是合法的。    如果你认为你现在是此类骗局的目标，请立即终止与他们的联系，并联系警方。

G |     相信你的直觉，如果听起来像是骗局，那很可能就是骗局。    进一步了解如何确保网上安全，或举报可疑诈骗，请访问https://netsafe.org.nz/     你也可以在https://www.police.govt.nz/advice-services/cybercrime-and-internet上找到预防网络犯罪的建议。         相关阅读：          房地产协会警告租户提防网上租房骗局，并提供了五点建议          2023年各类新骗局大曝光，如何避免落入圈套？          专家支招：如何避免落入社交媒体骗局？          注：本文为编译/原创，欢迎转发分享；但严禁复制等未经授权的非法使用。违反上述声明者，本网将追究其相关法律责任。使用授权请联系[email protected]。         chineseherald.co.nz All Rights Reserved 版权所有          (责编：twinkle)          相关内容                疫情通报：过去一周新西兰新增5575例           “三月疯狂”来了，奥克兰最堵路段大曝光！           气象局发警报：南岛惊现龙卷风，奥克兰小心雷暴           新西兰日常：13岁当劫匪，青少年光天化日打劫西区加油站......           怀特岛火山喷发22人遇难！这些公司判赔上千万！但尴尬的是…           一波三折！总理表态：退钱！不再申领住宿津贴           新中两国科学家合作研究获得突破：可用二氧化碳生产燃料           气候预警：本周末全国大范围将迎狂风和暴雨，奥克兰也在内！。

H |

Current article:http://www.roubutianquegumaigoubingdian.cyou/list_1aygf/170z.ppt

Published on:04:55:45